Granulocyte Colony-Stimulating Factor Given to Donors before Apheresis Does Not Prevent Aplasia in Patients Treated with Donor Leukocyte Infusion for Recurrent Chronic Myeloid Leukemia after Bone Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 3 A, 2000, Pages 321-326

  Flowers, Maiy E D ^a,b   Leisenring, Wendy ^a   Beach, Kathy ^a   Riddell, Stanley ^a   Radich, Jerald P ^a   Higano, Celestia S ^a   Rowley, Scott D ^a   Chauncey, Thomas R ^a   Bensinger, William I ^a   Sanders, Jean E ^a   Anasetti, Claudio ^a   Storb, Rainer ^a   Wade, James ^a   Appelbaum, Frederick R ^a   Martin, Paul J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Adoptive immunotherapy; G CSF; Graft versus host disease

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR MARKER; TUMOR PROTEIN;

ADOLESCENT; ADULT; APHERESIS; APLASTIC ANEMIA; ARTICLE; BLOOD; BLOOD DONOR; BONE MARROW TRANSPLANTATION; CHILD; COMPARATIVE STUDY; EVALUATION; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOCYTE TRANSFUSION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA; PREMEDICATION; RECURRENT DISEASE; SALVAGE THERAPY; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BLOOD COMPONENT REMOVAL; BLOOD DONORS; BONE MARROW TRANSPLANTATION; CHILD; COMBINED MODALITY THERAPY; FEMALE; FUSION PROTEINS, BCR-ABL; GRAFT REJECTION; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LEUKOCYTE TRANSFUSION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREMEDICATION; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0033649353     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70057-7     Document Type: Article

References (39)

1. Thomas ED, Clift R. Allogeneic transplantation for chronic myeloid leukemia. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Boston, MA: Blackwell Science; 1998:807-816.
2. Barrett AJ, Rhee F. Graft-versus-leukemia. In: Goldman JM, ed. Bailliere's Clinical Haemotology: Chronic Myeloid Leukaemia. London, UK: Bailliere Tindall W.B. Saunders; 1997:337-355.
3. Apperley JF, Mauro FR, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol. 1988;69:239-245.
4. Higano CS, Raskind WH, Singer JW. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood. 1992;80:1437-1442.
5. Higano CS, Chielens D, Raskind W, et al. Use of alpha-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood. 1997;90:2549-2954.
6. Arcese W, Goldman JM, D'Arcangelo E, et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood. 1993;82:3211-3219.
7. Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11:304-313.
8. Apperley JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse. Bone Marrow Transplant. 1986;1:53-66.
9. +T cell responses. Bone Marrow Transplant. 1992;9:355-364.
10. Korngold R, Leighton C, Manser T. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation. 1994;58:278-287.
11. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant. 1991;8:51-58.
12. Berger M, Wettstein PJ, Korngold R. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation. 1994;57: 1095-1102.
13. Pion S, Fontaine P, Baron C, Gyger M, Perreault C. Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy. J Clin Invest. 1995;95:1561-1568.
14. Kolb HJ, Mittermuller J, Clemm CH, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
15. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87:2195-2204.
16. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood. 1992;79:1379-1381.
17. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310-2318.
18. Bar BM, Schattenberg A, Mensink EJ, et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol. 1993;11:513-519.
19. Helg C, Roux E, Beris P, et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant. 1993;12:125-129.
20. Hertenstein B, Wiesneth M, Novotny J, et al. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation. 1993;56:1114-1118.
21. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100-106.
22. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
23. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86: 4337-4343.
24. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
25. Collins R, Shpilberg O, Drobyski W, et al. Donor leukocyte infusion in 140 patients with relapsed malignancy after allogeneic bone marrow transplant. J Clin Oncol. 1997;15:433-444.
26. Flowers MED, Sullivan KM, Deeg HJ. Graft-versus-host reactions: anti-leukemia effects of donor T cells. Transplant Proc. 1996;28:1184-1185.
27. Bryant E, Martin PJ. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Boston, MA: Blackwell Science; 1998:197-206.
28. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18: 295-304.
29. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
30. Loughran TP Jr, Sullivan K, Morton T, et al. Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990;76:228-234.
31. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995;85:2632-2638.
32. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons; 1980.
33. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood. 1996;88:2794-2800.
34. + T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp Med. 1998;187:1903-1920.
35. Van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusion before the onset of hematologic relapse. Blood. 1994;83:3377-3383.
36. + cells derived from granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells. Blood. 1997;89:1629-1634.
37. Mielcarek M, Torok-Storb B. Phenotype and engraftment potential of cytokine-mobilized peripheral blood mononuclear cells. Curr Opin Hematol. 1997;4:176-182.
38. Tanaka J, Mielcarek M, Torok-Storb B. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood. 1998;91:347-352.
39. Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by G-CSF-mobilized blood products: a mechanism for monocyte-mediated suppression of T cell proliferation. Blood. 1998;92:215-222.